Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved..
3C-like protease (3CLpro) processes and liberates functional viral proteins essential for the maturation and infectivity of severe acute respiratory syndrome coronavirus 2, the virus responsible for COVID-19. It has been suggested that 3CLpro is catalytically active as a dimer, making the dimerization interface a target for antiviral development. Guided by structural analysis, here we introduced single amino acid substitutions at nine residues at three key sites of the dimer interface to assess their impact on dimerization and activity. We show that at site 1, alanine substitution of S1 or E166 increased by twofold or reduced relative activity, respectively. At site 2, alanine substitution of S10 or E14 eliminated activity, whereas K12A exhibited ∼60% relative activity. At site 3, alanine substitution of R4, E290, or Q299 eliminated activity, whereas S139A exhibited 46% relative activity. We further found that the oligomerization states of the dimer interface mutants varied; the inactive mutants R4A, R4Q, S10A/C, E14A/D/Q/S, E290A, and Q299A/E were present as dimers, demonstrating that dimerization is not an indication of catalytically active 3CLpro. In addition, present mostly as monomers, K12A displayed residual activity, which could be attributed to the conspicuous amount of dimer present. Finally, differential scanning calorimetry did not reveal a direct relationship between the thermodynamic stability of mutants with oligomerization or catalytic activity. These results provide insights on two allosteric sites, R4/E290 and S10/E14, that may promote the design of antiviral compounds that target the dimer interface rather than the active site of severe acute respiratory syndrome coronavirus 2 3CLpro.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:298 |
---|---|
Enthalten in: |
The Journal of biological chemistry - 298(2022), 6 vom: 10. Juni, Seite 102023 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ferreira, Juliana C [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 29.06.2022 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jbc.2022.102023 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM340910992 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM340910992 | ||
003 | DE-627 | ||
005 | 20231226010543.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jbc.2022.102023 |2 doi | |
028 | 5 | 2 | |a pubmed24n1136.xml |
035 | |a (DE-627)NLM340910992 | ||
035 | |a (NLM)35568197 | ||
035 | |a (PII)S0021-9258(22)00463-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ferreira, Juliana C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2 |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.06.2022 | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. | ||
520 | |a 3C-like protease (3CLpro) processes and liberates functional viral proteins essential for the maturation and infectivity of severe acute respiratory syndrome coronavirus 2, the virus responsible for COVID-19. It has been suggested that 3CLpro is catalytically active as a dimer, making the dimerization interface a target for antiviral development. Guided by structural analysis, here we introduced single amino acid substitutions at nine residues at three key sites of the dimer interface to assess their impact on dimerization and activity. We show that at site 1, alanine substitution of S1 or E166 increased by twofold or reduced relative activity, respectively. At site 2, alanine substitution of S10 or E14 eliminated activity, whereas K12A exhibited ∼60% relative activity. At site 3, alanine substitution of R4, E290, or Q299 eliminated activity, whereas S139A exhibited 46% relative activity. We further found that the oligomerization states of the dimer interface mutants varied; the inactive mutants R4A, R4Q, S10A/C, E14A/D/Q/S, E290A, and Q299A/E were present as dimers, demonstrating that dimerization is not an indication of catalytically active 3CLpro. In addition, present mostly as monomers, K12A displayed residual activity, which could be attributed to the conspicuous amount of dimer present. Finally, differential scanning calorimetry did not reveal a direct relationship between the thermodynamic stability of mutants with oligomerization or catalytic activity. These results provide insights on two allosteric sites, R4/E290 and S10/E14, that may promote the design of antiviral compounds that target the dimer interface rather than the active site of severe acute respiratory syndrome coronavirus 2 3CLpro | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a 3-chymotrypsin-like protease | |
650 | 4 | |a 3CLpro | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a kinetic characterization | |
650 | 4 | |a thermodynamic stability | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a 3C-like proteinase, SARS-CoV-2 |2 NLM | |
650 | 7 | |a EC 3.4.22.- |2 NLM | |
650 | 7 | |a Coronavirus 3C Proteases |2 NLM | |
650 | 7 | |a EC 3.4.22.28 |2 NLM | |
650 | 7 | |a Alanine |2 NLM | |
650 | 7 | |a OF5P57N2ZX |2 NLM | |
700 | 1 | |a Fadl, Samar |e verfasserin |4 aut | |
700 | 1 | |a Rabeh, Wael M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of biological chemistry |d 1945 |g 298(2022), 6 vom: 10. Juni, Seite 102023 |w (DE-627)NLM000004995 |x 1083-351X |7 nnns |
773 | 1 | 8 | |g volume:298 |g year:2022 |g number:6 |g day:10 |g month:06 |g pages:102023 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jbc.2022.102023 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 298 |j 2022 |e 6 |b 10 |c 06 |h 102023 |